The Indegene IPO, valued at Rs 1,841.76 crores, comprises a combination of a fresh issue of 1.68 crore shares worth Rs 760.00 crores and an offer for sale of 2.39 crore shares totaling Rs 1,081.76 crores. Opening for subscription on May 6, 2024, and closing on May 8, 2024, the allotment is set to be finalized on Thursday, May 9, 2024.

Scheduled to list on BSE and NSE on Monday, May 13, 2024, the IPO's price band is fixed at ₹430 to ₹452 per share, with a minimum lot size of 33 shares. Retail investors need a minimum investment of ₹14,916, while for sNII, it is 14 lots (462 shares), amounting to ₹208,824, and for bNII, it is 68 lots (2,244 shares), amounting to ₹1,014,288.

The book running lead managers include Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, and Nomura Financial Advisory And Securities (India) Pvt Ltd, with Link Intime India Private Ltd serving as the registrar for the issue.

The Offer comprises the Fresh Issue of 16,814,159 Equity Shares aggregating up to ₹7,600 million by Company and the Offer for Sale of up to 23,932,732 Equity Shares aggregating up to ₹1,0817.6 million by the Selling Shareholders.

Net Proceeds will be utilized towards

1. Repayment/prepayment of indebtedness of one of our Material Subsidiaries, ILSL Holdings, Inc.
2. Funding the capital expenditure requirements of our Company and one of our Material Subsidiaries, Indegene, Inc.
3. General corporate purposes and inorganic growth.

The company provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products.

It is critical for the business to regularly update information technology infrastructure and provision for a growing workforce. The company also continues to upgrade the infrastructure within its office premises to accommodate the growing talent pool.

Read more

About Indegene Limited

The company provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Enabling life sciences companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient, and modern manner.

The portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations of life sciences companies. The company has established client relationships with the 20 largest (by revenue) biopharmaceutical companies in the world for FY23, earning more than 69.00% of total revenue from operations.

While there are talent gaps and margin pressures, life sciences companies are placing greater emphasis on digital innovation and enterprise-wide transformation initiatives to improve operational efficiencies.

As of December 31, 2023, the company had a total of 65 active clients. The company operates from operation hubs located across North America, Europe, and Asia. The company has internally developed artificial intelligence (“AI”) and machine learning (“ML”) based proprietary platforms, allowing them to offer solutions across the globe at scale.

Growth in life sciences operations expenditure, which was estimated at ₹12.0 trillion (US$156 billion) in 2022 is expected to grow at a CAGR of 6.5% to reach ₹15.5 trillion (US$201 billion) in 2026.

Sales and marketing was the largest segment of life sciences operations expenditure, contributing ₹4.2 trillion (US$55 billion) or 35% of overall life sciences operations expenditure, but with a low outsourcing penetration rate of 7 – 12%. However, outsourcing expenditure in this segment is projected to grow at a CAGR of approximately 14.5% between 2022 and 2026, representing room for growth.

The regulatory and medical affairs segment and the pharmacovigilance segment together accounted for ₹3.5 trillion (US$45 billion) or 29% of overall life sciences operations expenditure.

Risk Associated to the Issue:

• Solely focused on life sciences industry: All of revenues are earned from clients in the life sciences industry, a significant portion of which is attributable to clients in the biopharmaceutical industry.
• Concentrated customers: Significant portion of business is attributable to certain large clients located in North America and Europe. From top five customers holds 47.76% and top ten customers holds 66.71% revenue.
• Revenues are derived from Subsidiaries: Indegene Limited holds 6.46%, Indegene, Inc. holds 79.56%, and Other subsidiaries hold 13.98% revenue from operations.
• High Competition and difficult to predict industry.
• Reliance on sub-contractors and third-party service providers: - The company execute arrangements with sub-contractors and third-party vendors to provide services including: (i) quality control services for pharmacovigilance; (ii) payroll services; (iii) software and web development; (iv) quality assurance; (v) medical information support; and (vi) campaign management.
• Management of attrition and attraction of skilled professionals is a key task.
• The adoption of generative artificial intelligence (“Gen AI”) by the life sciences industry could lead to changes in customers’ operations and, in turn affecting revenue and profitability.
• Complex management due to international operations:- International operations exposes company to complex management, legal, tax and economic risks, and exchange rate fluctuations, which could adversely affect business.